106 related articles for article (PubMed ID: 8300134)
1. Clinical course of ovarian cancer patients under repeated stimulation of HAMA using MAb OC125 and B43.13.
Baum RP; Noujaim AA; Nanci A; Moebus V; Hertel A; Niesen A; Donnerstag B; Sykes T; Boniface G; Hör G
Hybridoma; 1993 Oct; 12(5):583-9. PubMed ID: 8300134
[No Abstract] [Full Text] [Related]
2. Influence of human anti-murine antibodies on in vitro assays in ovarian cancer patients.
Hertel A; Baum R
Hybridoma; 1993 Oct; 12(5):571-6. PubMed ID: 8300132
[No Abstract] [Full Text] [Related]
3. Are human anti-idiotypic anti-OC125 antibodies formed after immunization with the anti-CA125 antibody B43.13?
Reinsberg J; Krebs D
Hybridoma; 1997 Feb; 16(1):59-63. PubMed ID: 9085130
[TBL] [Abstract][Full Text] [Related]
4. Idiotypic cascades after MAb OC125 application.
Reinsberg J
Hybridoma; 1993 Oct; 12(5):577-82. PubMed ID: 8300133
[No Abstract] [Full Text] [Related]
5. False changes in CA 125 levels in ovarian cancer patients after infusion of OC125 fragments for diagnostic and therapeutic purpose.
Reinsberg J; Wagner U; Krebs D
Arch Gynecol Obstet; 1994; 255(1):9-18. PubMed ID: 8042882
[TBL] [Abstract][Full Text] [Related]
6. Anti-murine antibody response to mouse monoclonal antibodies in cancer patients.
Sakahara H; Saga T; Onodera H; Yao Z; Nakamoto Y; Zhang M; Sato N; Nakada H; Yamashina I; Endo K; Konishi J
Jpn J Cancer Res; 1997 Sep; 88(9):895-9. PubMed ID: 9369938
[TBL] [Abstract][Full Text] [Related]
7. Influence of MAb (F(Ab)2 OC 125 on the survival rate of ovarian carcinoma patients.
Nesselhut T
Hybridoma; 1993 Oct; 12(5):567-70. PubMed ID: 8300131
[No Abstract] [Full Text] [Related]
8. Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival.
Miotti S; Negri DR; Valota O; Calabrese M; Bolhuis RL; Gratama JW; Colnaghi MI; Canevari S
Int J Cancer; 1999 Feb; 84(1):62-8. PubMed ID: 9988234
[TBL] [Abstract][Full Text] [Related]
9. Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13.
Madiyalakan R; Sykes TR; Dharampaul S; Sykes CJ; Baum RP; Hör G; Noujaim AA
Hybridoma; 1995 Apr; 14(2):199-203. PubMed ID: 7590780
[TBL] [Abstract][Full Text] [Related]
10. Anti-idiotypic monoclonal antibodies against anti-ovarian carcinoma monoclonal antibody COC166-9. Generation and application.
Qian HN; Lu WY
Chin Med J (Engl); 1994 Feb; 107(2):99-103. PubMed ID: 8194388
[TBL] [Abstract][Full Text] [Related]
11. Specific and nonspecific immunoassays to detect HAMA after administration of indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody to patients with ovarian cancer.
Massuger LF; Thomas CM; Segers MF; Corstens FH; Verheijen RH; Kenemans P; Poels LG
J Nucl Med; 1992 Nov; 33(11):1958-63. PubMed ID: 1432156
[TBL] [Abstract][Full Text] [Related]
12. Evidence for interaction of human anti-idiotypic antibodies with CA 125 determination in a patient after radioimmunodetection.
Reinsberg J; Heydweiller A; Wagner U; Pfeil K; Oehr P; Krebs D
Clin Chem; 1990 Jan; 36(1):164-7. PubMed ID: 2297919
[TBL] [Abstract][Full Text] [Related]
13. Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor.
Crombet T; Torres O; Neninger E; Catalá M; Rodríguez N; Ramos M; Fernández E; Iznaga N; Pérez R; Lage A
Cancer Biother Radiopharm; 2001 Feb; 16(1):93-102. PubMed ID: 11279803
[TBL] [Abstract][Full Text] [Related]
14. Clinical immunoscintigraphy of ovarian carcinoma using iodine-131-labeled 145-9 monoclonal antibody.
Chung JK; Kang SB; Lee HP; Lee MC; Koh CS; Sakahara H; Endo K
J Nucl Med; 1993 Oct; 34(10):1651-5. PubMed ID: 8410277
[TBL] [Abstract][Full Text] [Related]
15. Human antiidiotypic antibodies against OC125 strongly interfere with one-step assays of CA 125 employing OC125 and M11 antibodies.
Reinsberg J; Gast B
Clin Chem; 1994 Jun; 40(6):951-2. PubMed ID: 8087996
[No Abstract] [Full Text] [Related]
16. Falsely low results in CA 125 determination due to anti-idiotypic antibodies induced by infusion of [131I]F(ab')2 fragments of the OC125 antibody.
Reinsberg J; Nocke W
Eur J Clin Chem Clin Biochem; 1993 May; 31(5):323-7. PubMed ID: 8357942
[TBL] [Abstract][Full Text] [Related]
17. [A trial with immunotherapy of ovarian cancer by idiotype vaccination. Activation of the idiotype network in patients with advanced ovarian cancers by treatment with monoclonal antibody OC125].
Wagner U; Reinsberg J; Krebs D
Geburtshilfe Frauenheilkd; 1990 Oct; 50(10):785-8. PubMed ID: 2286317
[TBL] [Abstract][Full Text] [Related]
18. [Radioimmunoimaging assay of ovarian tumor with 99mTc labeled anti-carcinoembryonic antigen monoclonal antibody].
Wu LY; Wu AR; Zhan J
Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):340-2, 381-2. PubMed ID: 8001407
[TBL] [Abstract][Full Text] [Related]
19. Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo.
Noujaim AA; Schultes BC; Baum RP; Madiyalakan R
Cancer Biother Radiopharm; 2001 Jun; 16(3):187-203. PubMed ID: 11471484
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network.
Wagner UA; Oehr PF; Reinsberg J; Schmidt SC; Schlebusch HW; Schultes B; Werner A; Prietl G; Krebs D
Biotechnol Ther; 1992; 3(1-2):81-9. PubMed ID: 1305894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
